Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolumar is a nutraceutical supplement developed by the Italian company Ghimas S.p.A., specifically formulated to support joint health and manage symptoms of degenerative joint conditions such as osteoarthritis. The product contains a synergistic combination of **glucosamine sulfate**, **chondroitin sulfate**, and **Vitamin C** (ascorbic acid). Glucosamine and chondroitin are fundamental components of articular cartilage, serving as precursors for the synthesis of glycosaminoglycans and proteoglycans, which maintain the elasticity and shock-absorbing properties of the joint matrix. Vitamin C acts as an essential cofactor for the enzyme prolyl hydroxylase, which is required for the stabilization of collagen fibers. By providing these structural building blocks and supporting enzymatic repair processes, Tolumar aims to preserve cartilage integrity and reduce the progression of joint wear.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tolumar.